The potential roles of retinoids in combating drug resistance in cancer: implications of ATP-binding cassette (ABC) transporters

Mohamed R. Abdelaal\textsuperscript{1,2} and Hesham Haffez\textsuperscript{1,2}

\textsuperscript{1}Biochemistry and Molecular Biology Department, Faculty of Pharmacy, and \textsuperscript{2}Centre of Scientific Excellence Helwan Structural Biology Research (HSBR'), Helwan University, Cairo 11795, Egypt

Multidrug resistance (MDR) means that tumour cells become unresponsive during or after the course of treatment to one or more of chemotherapeutic drugs. Chemotherapeutic resistance critically limits the treatment outcomes and remains a key challenge for clinicians. The alteration in intracellular drug concentration through the modulation of its transport across the plasma membrane is the major cause for MDR and is adopted by various mediators, including ATP-requiring enzymes (ATPases). Among these ATPases, ABC transporters have been extensively studied, and found to be highly implicated in tumorigenesis and MDR. The present review sheds light on the documented effects of retinoids on ABC enzymes to understand their mechanism in combating cancer cell resistance. This would open the gate to test the mechanism and applicability of different new synthetic retinoids in literature and market as modulators of ATP-dependent efflux pumping activity, and promote their applicability in diminishing anti-cancer drug resistance.

1. Introduction

Multidrug resistance (MDR) occurs when cancer cells become progressively unresponsive to anti-cancer drugs independently of their structures and/or mechanisms of action [1]. MDR might arise due to alteration in drug target molecules, interrupted access to target cells, genetic responses, enhanced DNA repair mechanisms, counteracting growth factors, metabolic effects or altered transport of the chemotherapeutic agent across the plasma membrane [1–4]. The latter mechanism is mediated by a wide range of ATP-requiring enzymes (ATPases). ATPase family members are indispensable enzymes for both normal and cancer cells [5]. They are widely distributed within cells and differ considerably in structures and biological activities. They share the ability to hydrolyse the phosphate $\gamma\beta$ bond of ATP to release free energy that is harnessed subsequently by the enzyme to perform its biological functions [6]. ATPase superfamily comprises ATP-binding cassette (ABC) transporters, P-type ATPases, V-type ATPases, kinesins, helicases, heat-shock proteins as well as ATPases associated with different cellular activities (AAA-ATPases) [5,7]. Of special interest, ABC transport systems have been extensively studied as mediators of MDR in various types of cancer [8].

Although ABC transport systems are constitutively expressed in normal and cancer cells, their expression is also modulated by external factors, like retinoids. In the last few decades, it has become increasingly evident that retinoids, alone or in combinations, are promising anti-cancer compounds with considerable potency [9]. Significant correlation has been described between retinoids and ATPase transporters in cancer [10–12]. Besides the deregulation of ATPase gene expression after treatment with retinoids, ATRA and its analogues were found to be substrates for the MDR transporters and thus exposed to variations in
their intracellular concentration leading to pharmacokinetic disturbances and variable anti-cancer response [13,14]. Figure 1 and table 1 summarizes the chemical structures and possible activity of retinoids by either re-sensitizing multiple MDR cell lines to chemotherapy or inducing direct growth inhibition of these MDR cells. Interestingly, the concentrations of retinoids needed for the demise of 50% of cultured cells growth (IC₅₀) were found to be at, or slightly lower than, the micromolar scale [9,66,73,74]. Given this potency, more deep insights into the interplay between retinoids and MDR-conferring ATPases are still needed.

2. The interplay between ABC transporters and MDR

Among the currently known ABC genes in the human genome, perturbations in the expression levels of some of these transporters are implicated in various human diseases, including cancer [30]. Furthermore, ABC transporters are highly associated with MDR [31–35]. Members of the ABCB, ABCC and ABCG subfamilies are major determinants for the emergence of MDR [36]. Most importantly, P-gp, BCRP and multidrug resistance-associated protein-1 (MRP-1 or ABCC-1) are the best characterized [31–35]. The induction of the expression of these ATP-requiring proteins leads to significant changes in the signalling of many ions and molecules promoting tumorigenesis, including metal ions, vitamins and carbohydrates [5,37,38]. More profoundly, these efflux transporters pump a wide range of structurally diverse anti-cancer compounds outside the cell, reducing their bioavailability and therapeutic potential [1,39]. The overexpression of P-gp, BCRP and/or MRP-1 confers significant resistance to various neutral and cationic hydrophobic chemotherapeutic compounds [40–42]. These observations highlight the intimate link between disturbances in ABC transporters and conferred drug resistance, leading subsequently to increased tumour burden and reduced treatment outcomes.

As expected, inhibition of the pumping activity of the ABC transporter enzymes often leads to an increased cellular concentration of the cytotoxic drugs, and thus greater anti-cancer activity and reduced MDR [43]. Despite their structural differences, P-gp and BCRP share several common ligands that are transported across cell membrane [44–46]. These translocated ligands are collectively called allocrites [47]. Although they are functionally similar, P-gp and BCRP share only about 20% protein sequence identity in the NBDs with no significant sequence identity in the TMDs [48–51]. Nevertheless, both share various anti-cancer allocrites giving rise to MDR. The structural insights into the interactions between ABC transporters and their ligands show clearly that the hydrophobic nature of allocrites, including the retinoic acid and its analogues (or retinoids), is one of the major determinants of their ability to communicate with the transporters [48,52–58]. Finding chemosensitizers that are both effective and safe and could help rescue the emerging resistance to standard chemotherapeutic compounds in cancer is still needed.

3. Natural retinoids induce alternations in ABC transporters on different levels including expression, activity and binding interaction

The data available in the literature showed some examples of natural retinoids that proved their ability to modulate ABC transporters in cancer types on different levels and reverse MDR. For instance, retinol caused significant reduction in
P-gp expression in colorectal carcinoma cells (CRC) leading to enhanced anti-tumor efficacy of etoposide [24,59]. In leukaemia, cell line L1210, ATRA caused transcriptional repression of P-gp enhancing the activity of verapamil substrate [19]. Interestingly, the latter effect was not attributed to the direct binding of RAR merely to the \textit{ABCB1} promoter; instead, it appears to be mediated by RXR\textgreek{a} sequestration after RAR-RXR\textgreek{a} heterodimer formation [19]. As a result, fewer RXR\textgreek{a} may be available to mediate the binding of ABCB1-activating progesterone-X-receptor (PXR) to \textit{ABCB1} promoter. These results suggest that retinoic acid and related isomers attenuate the ABC transporter through modulation of mRNA expression levels.

On the level of ATPase activity, \textit{Spodoptera frugiperda} (Sf9) membrane preparations expressing P-gp and BCRP was used to investigate the effects of some natural retinoids with verapamil and quercetin as their substrates respectively [10,11]. The study showed retinol and 13-cis-RA could significantly inhibit both the basal and the substrate-stimulated ATPase activity while ATRA, 9-cis-RA, retinyl-propionate and retinyl-palmitate did not have these effects. [11]. The ATPase inhibitory effect of retinoids observed in these experiments might be rooted in the hypothesis of retinoid-induced allosteric inhibition in activity of the transporters, related either to the competitive inhibition caused by direct interaction of retinoids with the substrate-binding site (s), or the membrane structural changes induced by retinoids.

On the level of binding interaction, studies revealed the interaction of ATPases with retinoic acid analogues to be stereospecific [11,53,60]. For example, 13-cis-RA inhibited both P-gp and BCRP transporters, while its stereoisomers ATRA and 9-cis-RA did not influence the enzymatic activity.

| retinoid | class | resistant cancer cell line | cancer origin | resistance to chemotherapeutic agent(s) | IC\textsubscript{50} (µM) | Ref. |
|----------|-------|---------------------------|---------------|----------------------------------------|----------------|-----|
| ATRA     | retinoic acid receptor (RAR) Pan-agonist | MDA-MB-231 | breast | paclitaxel (PTX) and 5-fluorouracil (5-FU) | 34.1\textsuperscript{b,c} | [15,16] |
| LoVo/MDR | colon | doxorubicin (Dox) | NA\textsuperscript{d} | [17] |
| HEN-16-2/CDPP | cervical | cisplatin (CDDP) | NA\textsuperscript{d} | [18] |
| L1210/VCR | mouse lymphocytic leukaemia | vincristine (VCR) | NA\textsuperscript{d} | [19,20] |
| mS-0.5 | melanoma | colchicine | NA\textsuperscript{d} | [21] |
| J82-NVB | bladder | navelbine | NA\textsuperscript{d} | [22] |
| HL60/DNR | acute promyelocytic leukaemia (APL) | daunorubicin | NA\textsuperscript{d} | [23] |
| retinol class | — | SW620 | colorectal | etoposide | NA\textsuperscript{d} | [24] |
| isoxazole retinoid | RAR pan-agonist | HL60R | APL | ATRA | 1.4\textsuperscript{b,c} | [25] |
| 15b | — | K562 | leukaemia | ATRA | 2.3\textsuperscript{b,c} | [25] |
| | — | HUT78 | T-cell lymphoma | ATRA | 0.8\textsuperscript{b,c} | [25] |
| fenretinide or 4-HPR | RAR-\textbeta selective agonist | Bel-7402 | HCC | Dox and VCR | 13.1\textsuperscript{a} | [26,27] |
| | — | MDA-MB-231 | breast | PTX and 5-FU | 6.5\textsuperscript{b,c} | [28] |
| | — | CHLA-119 | neuroblastoma | ABT-737 (small-molecule BH3 mimetic) alone | NA\textsuperscript{d} | [29] |
| | — | ABPN (or CBG41) | RAR pan-agonist | MDA-MB-231 | breast | PTX and 5-FU | 3.3\textsuperscript{b,c} | [28] |
| | — | ATPR | RAR pan-agonist | MDA-MB-231 | breast | PTX and 5-FU | 18.4\textsuperscript{b,c} | [15] |

\textsuperscript{a}IC\textsubscript{50} (concentration of the compound caused 50% reduction in comparison to untreated cells) was calculated after 72 h of treatment.

\textsuperscript{b}IC\textsubscript{50} was calculated after 48 h of treatment.

\textsuperscript{c}IC\textsubscript{50} was calculated after 24 h of treatment.

\textsuperscript{d}NA = not available.

Table 1. The chemo-sensitizing effect of natural and synthetic retinoids on MDR cell lines.
interaction and binding affinity with MDR-related ATPases, and suggest that minute differences in their structure might substantially influence the ATPase enzymatic activity.

4. The MDR-reversing activity of synthetic retinoids

The main obstacles of using formulations delivering natural retinoids into the systemic circulation are in vitro photo-instability [61–66] and in vivo enzymatic catabolism [67–70]. Therefore, there was urgent need for development of synthetic retinoic acid analogues, which mimic the biological actions and physico-chemical characteristics of natural ones, and to reverse MDR induced by cancer cells [9,71–76]. A heterocycle-containing retinoid called isoxazole retinoid 15b (figure 1) was synthesized and used to reverse the MDR activity of an acute promyelocytic leukaemia ATRA-resistant cell line called HL60R (table 1) [25]. This synthetic retinoid 15b rendered the cells more prone to the growth-inhibitory activity of ATRA and reactivated the cellular apoptosis pathway. Fenretinide [28], ABPN [28] and ATPR [15] (figure 1) are further examples of synthetic retinoids that were able to sensitize multi-drug resistant triple-negative breast cancer to paclitaxel and 5-fluorouracil. Nevertheless, these promising in vitro results need to be confirmed in vivo using chemo-resistant cancer animal models exposed to standard chemotherapeutics plus synthetic retinoids.

Despite this MDR-reversing activity in various cancers, an early report showed the cross-resistance to CD437 (a synthetic RARγ-selective agonist; figure 1) in paclitaxel-resistant human ovarian cancer cells which are overexpressing P-gp [77]. Others claimed that N-(4-hydroxyphenyl) retinamide (4HPR, aka fenretinide; figure 1) could potentiate the cytotoxicity of cisplatin in ovarian [78], breast [79] and lung [80] cancers. The underlying cause of this chemo-sensitization can be explained in light of the dose perspective point of view. Active doses from natural retinoids in blood are few in nanomolar range (1–20 nanomolar) [81] compared to the stable synthetic retinoids that can be taken through either parenteral or oral administration with relatively sufficient high local retinoid concentrations in the blood. The available doses of synthetic retinoids were able to subsequently block P-gp and BCRP expressed at the surface of resistant cancer cells [82–85].

5. Concluding remarks

Understanding of cancer resistance has evolved over the past few decades, and cancer resistance is suggested to be related to loss of retinoid-ABC transporter signalling. Also, emerging evidence sheds light on the development of MDR and the roles played by ATPases in chemotherapy resistance. Unfortunately, current chemotherapy regimens lead to limited efficacy and an upsurge in the number of cells with high levels of expression of ABC transporters. Various chemical compounds have been identified and tested to modulate or inhibit the transport function of ABC transporters, including P-gp and BCRP, and thus chemo-sensitize multidrug-resistant cancer cells. Nevertheless, ABC-modulatory compounds showing great potential on the bench frequently failed to prove efficacy in the clinic. Therefore, this presents a formidable challenge to medicinal chemists and structural biologists in defining P-gp and BCRP substrates with new structural diversity to modulate P-gp- and BCRP-mediated drug transport including retinoids. This requires precise knowledge of their structural domains and the exact mechanisms of interactions. Given that modulation of the ABC transporters might influence the pharmacokinetics of other co-administered chemotherapeutic drugs, more care should be taken upon the combination of retinoids with other anti-cancer drugs to avoid drug-drug interactions occurring at the level of the membrane transporters, P-gp and BCRP.

Considering the anti-cancer potency of synthetic retinoids, future research should focus on unravelling the impact of these compounds on the expression and activity of efflux pumps and other drug transporters. This could pave the way for recruiting synthetic retinoids as chemosensitizers that specifically target MDR-promoting transporters and could help in fighting the battle against chemoresistance.

Data accessibility. This article has no additional data.

Authors’ contributions. M.R.A.: conceptualization, methodology, validation, writing—original draft, writing—review and editing; H.H.: conceptualization, investigation, methodology, project administration, supervision, writing—original draft, writing—review and editing.

Both authors gave final approval for publication and agreed to be held accountable for the work performed therein.

Conflict of interest declaration. We declare that we have no competing interests.

Funding. This work was supported by the Egyptian Academy of Scientific Research and Technology (ASRT) under the grant call ‘National Program for Research and Innovation in Health and Biomedical Sciences’ (ID: PRISM _ 5173), 2020–2022.

References

1. Bukowski K, Kciuk M, Kontek R. 2020 Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21, 3233. (doi:10.3390/ijms21093233)
2. Nikolau M, Pavlopoulu A, Georgakiou AG, Kyriodimos E. 2018 The challenge of drug resistance in cancer treatment: a current overview. Clin. Exp. Metastasis. 35, 309–318. (doi:10.1007/s10585-018-9903-0)
3. Arendshofer C, Menéndez JC. 2002 Inhibitors of multidrug resistance antitumor agents (MDR). Curr. Med. Chem. 9, 159–193. (doi:10.2174/092986702371175)
4. Luqmani YA. 2005 Mechanisms of drug resistance in cancer chemotherapy. Med. Prin. Pract. 14(Suppl 1), 35–48. (doi:10.1159/000086183)
5. Chène P. 2003 The ATPases: a new family for a family-based drug design approach. Expert Opin. Ther. Targets. 7, 453–461. (doi:10.1517/14728222.7.3.453)
6. Zhang S, Mao Y. 2020 AAA+-ATPases in protein degradation: structures, functions and mechanisms. Biomolecules 10, 629. (doi:10.3390/biom10040629)
7. Thomas C et al. 2020 Structural and functional diversity calls for a new classification of ABC transporters. FEBS Lett. 594, 3767–3775. (doi:10.1002/1873-4868.13935)
8. Xu SW et al. 2020 SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. Pharmacol. Res. 153, 104660. (doi:10.1016/j. phrs.2020.104660)
9. Abdelaal MR, Soror SH, Elmagar MR, Hafiez H. 2021 Revealing the potential application of EC-synthetic retinoid analogues in anticancer therapy. Molecules 26, 506. (doi:10.3390/molecules26020506)
10. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. 1992 Expression of the human multidrug resistance DNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267, 4854–4858. (doi:10.1016/S0021-9258(18)42909-2)
21. Stromskaja T, Filipova NA, Rybalkina E, Egudina SV, Shitl4A, Elleseenova AV, Stavnoryakova AA. 1995 Alterations of melanin synthesis in human melanoma cells selected in vitro for multidrug resistance. Exp. Toxicol. Pathol. 47, 157–166. (doi:10.1007/s00490-993(11)80308-8)

22. Debal V, Brelloult F, Manfait M. 1997 Concomitant decrease of resistance and modifications of the cytoskeleton after all-trans retinoic acid and phorbol ester treatments in a naveline-resistant bladder carcinoma cell line. Anticancer Res. 17, 1147–1154. (doi:10.1038/bjc.1994.458)

23. Zhou DC, Marie JP, Maisonneuve L, Faussat-Suberville AM, Zouitoun R. 1993 Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant hematopoietic HL60/DNR cell line. Exp. Hematol. 21, 779–784.

24. Klamt F, Passos DT, Castro MA, Gelain DP, Grivicich I, Moreira J.C. 2008 Inhibition of MDR1 expression by retinol treatment increases sensitivity to etoposide (VP16) in human neoplastic cell line. Toxicol. In Vivo 22, 873–878. (doi:10.1016/j.tiv.2008.01.004)

25. Simonni D et al. 2001 Heterocycle-containing retinoids. Discovery of a novel isoaxazole antitumoral possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. J. Med. Chem. 44, 2308–2318. (doi:10.1021/jm0010320)

26. Shentu J, Zhang B, Fan L, He Q, Yang B, Chen Z. 2007 Anti-proliferative activity of fenitine in human hepatoma cells in vitro and in vivo. Anticancer Drugs 18, 47–53. (doi:10.1097/CAD.0b013e3280eeb5f)

27. Huang M, Liu G. 1999 The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 135, 97–105. (doi:10.1016/S0304-3835(98)00280-8)

28. Um SJ, Han KS, Kwon YJ, Park SH, Rho YS, Sin HS, Park JS. 2003 Novel retinoid acid derivative ABPN possesses potent inhibitory activity on cell growth and apoptosis in cancer cells. Int. J. Cancer. 107, 1038–1046. (doi:10.1002/ijc.11489)

29. Fang H, Harne TM, Kalosu O, Maldonado V, DeCleeck YA, Reynolds CP. 2011 Synergistic activity of fenestinide and the Bc-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin. Cancer Res. 17, 7093–7104. (doi:10.1186/1078-0432-cc-11-0578)

30. Wiltens S. 2015 Structure and mechanism of ABC transporters. F1000Prime Rep. 7, 14. (doi:10.12703/ F7-14)

31. Yoshizawa K, Nozaki S, Kitahara H, Ohara T, Kato K, et al. 2019 ABC Transporter-mediated multidrug-resistant cancer. Curr. Cancer Drug Targets. 21, 570–594. (doi:10.2174/1568009121795164048)

32. Washio I, Nakashiki T, Ishiguro N, Bister T, Tamai I. 2019 Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug colon cancer cell lines. Biopharm. Drug Dispos. 40, 32–43. (doi:10.1002/bdd.2167)

33. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE. 2009 An unexpected synergistic role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-(3-chloro-4- [(3-fluorobenzyl)oxy]phenyl)-6-[5-({[2- (methylsulfonyl)ethyl]aminomethyl)2-furyl]-4- quinazolinamine; GW572016). Drug Metab. Dispos. 37, 439–442. (doi:10.1124/dmd.108.024646)

34. Egido E, Muller R, Blattert B, Merino G, Seeig A. 2015 Predicting activators and inhibitors of the breast cancer resistance protein (ABCG2) and P-Glycoprotein (ABCB1) based on mechanistic considerations. Mol. Pharm. 12, 4026–4037. (doi:10.1021/acs.molpharmaceut.5b00463)

35. Holland IB, Bliht MA. 1999 ABC ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J. Mol. Biol. 293, 381–399. (doi:10.1006/jmbi.1999.2993)

36. Ni Z, Mark ME, Cai X, Mao Q. 2010 Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. Int. J. Biochem. Mol. Biol. 1, 1–11.
49. Homolya L, Hollá Z, Gemmann UA, Pastan I, Gottesman MM, Sarkadi B. 1993 Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268, 21493–21496. (doi:10.1016/S0021-9258(00)00366-3)

50. Gottesman MM, Pastan I. 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427. (doi:10.1146/annurev.bi.62.070193.002125)

51. Li-Blatter X, Beck A, Seelig A. 2012 P-glycoprotein-ATPase modulation: the molecular mechanisms. Biophys. J. 102, 1383–1393. (doi:10.1016/j.bpj.2012.02.018)

52. Xu Y, Egido E, Li-Blatter X, Müller R, Merino G, Bernetche S, Seelig A. 2015 Allosteric sensing and binding by the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). Biochemistry 54, 6195–6206. (doi:10.1021/acs.biochem.5b00649)

53. Aller SG et al. 2009 Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718–1722. (doi:10.1126/science.1168750)

54. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. 2010 Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab. 11, 603–617. (doi:10.2174/138920010792927325)

55. Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang J. 2017 Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res. 67, 4373–4381. (doi:10.1158/0008-5472.can-16-3169)

56. McDevitt CA, Collins RF, Conway M, Modok S, Storm V, Kerr ID, Ford RC, Callaghan R. 2006 Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14, 1623–1632. (doi:10.1016/j.str.2006.08.014)

57. Li J, Jaimes KS, Aller SG. 2014 Refined structures of geometrical isomers of retinoids. J. Nutr. Sci. Vitaminol. 43, 167–176. (doi:10.3177/jnsv.43.167)

58. Homolya L, Holló Z, Gemmann UA, Pastan I, Gottesman MM, Sarkadi B. 1993 Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268, 21493–21496. (doi:10.1016/S0021-9258(00)00366-3)

59. Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang J. 2017 Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res. 67, 4373–4381. (doi:10.1158/0008-5472.can-16-3169)

60. McDevitt CA, Collins RF, Conway M, Modok S, Storm V, Kerr ID, Ford RC, Callaghan R. 2006 Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14, 1623–1632. (doi:10.1016/j.str.2006.08.014)

61. Li J, Jaimes KS, Aller SG. 2014 Refined structures of mouse P-glycoprotein. Protein Sci. 23, 34–46. (doi:10.1002/pro.2387)

62. Rosenberg MF, Bikadi Z, Chan J, Liu X, Ni Z, Cai X, Ford RC, Mao Q. 2010 The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 18, 482–493. (doi:10.1016/j.str.2010.01.017)

63. Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, Thomazy V, Davies PJ. 1996 Enhanced anitumor efficacy of cisplatin in combination with ALR10157 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin. Cancer Res. 2, 511–520.

64. Dey S, Haakeyemyer P, Pastan I, Gottesman MM. 1999 A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry 38, 6630–6639. (doi:10.1021/bi980308i)

65. Murayama A, Suzuki T, Matsu M. 1997 Photol挨asomerization of retinoic acids in ethanol under room light: a warning for cell biological study of geometrical isomers of retinoids. J. Nutr. Sci. Vitaminol. 43, 167–176. (doi:10.3177/jnsv.43.167)